allg
| Field | Value | Source |
|---|---|---|
| Human milk lactoferrin concentration in colostrum | 6.7 g/L | Section 1. Lactoferrin: A Brief Overview |
| Human milk lactoferrin concentration in transitional milk | 3.7 g/L | Section 1. Lactoferrin: A Brief Overview |
| Human milk lactoferrin concentration in mature milk | 2.6 g/L | Section 1. Lactoferrin: A Brief Overview |
| Human lactoferrin molecular weight | 80 kDa | Section 1. Lactoferrin: A Brief Overview |
| Human lactoferrin amino acid count | 691 amino acids | Section 1. Lactoferrin: A Brief Overview |
| Healthy human blood lactoferrin concentration | 0.02 to 1.52 µg/mL | Section 2. Lactoferrin Bioavailability: Absorption and Body Delivery |
| Bovine lactoferrin oral administration safety in rats | 2 g/kg per 13 days | Section 2. Lactoferrin Bioavailability: Absorption and Body Delivery |
| Recombinant human lactoferrin oral administration safety in humans | 1.5–9 g per 15 days | Section 2. Lactoferrin Bioavailability: Absorption and Body Delivery |
| Bovine lactoferrin clinical trial dosage for colorectal polyps | 1.5 or 3 g daily | Section 3. Lactoferrin and Cancer |
| Clinical trial participant age range | 40 to 75 years | Section 3. Lactoferrin and Cancer |
| Clinical trial duration | 1 year | Section 3. Lactoferrin and Cancer |
| Field | Value | Source |
|---|---|---|
| Quantitative dose-response data for specific cancer cell lines | null | null |
| Standardized pharmacokinetic parameters for oral lactoferrin in humans | null | null |
| Field | Value | Source |
|---|---|---|
| Bovine lactoferrin (bLf) purity | about 98% | Materials and Methods |
| Bovine lactoferrin (bLf) iron saturation | about 7% | Materials and Methods |
| LPS contamination of bLf | 0.6 ± 0.05 ng/mg of bLf | Materials and Methods |
| Vero E6 inhibition (100 μg/ml bLf, MOI 0.1) | about one log | Results |
| Vero E6 inhibition (100 μg/ml bLf, MOI 0.01) | about two log | Results |
| bLf-spike CTD1 interaction energy (MM/GBSA) | -28.02 kcal/mol | Computational Results |
| hLf-spike interaction energy (MM/GBSA) | -48.25 kcal/mol | Computational Results |
| Number of bLf-spike persistent interactions | 28 | Computational Results |
| Number of hLf-spike persistent interactions | 45 | Computational Results |
| Field | Value | Source |
|---|---|---|
| Dose-response curve for bLf antiviral activity | null | null |
| IC50 value of bLf against SARS-CoV-2 | null | null |
| Field | Value | Source |
|---|---|---|
| Lactoferrin concentration in colostrum vs mature milk | Up to seven times more in colostrum | Section 2 |
| Molecular weight of secreted lactoferrin | About 80 kDa | Section 2 |
| Number of amino acids in secreted lactoferrin | 689 | Section 2 |
| Thermal stability of lactoferrin | Resistant to heating for several hours at 56 °C; denatures above 80–90 °C | Section 2 |
| N-linked glycosylation sites in human lactoferrin | 3 | Section 2 |
| N-linked glycosylation sites in bovine lactoferrin | 5 | Section 2 |
| Lactoferrin content in cow's milk | 25-75 mg per glass | Section 2.2 |
| Sequence similarity between human and bovine lactoferrin | 77% | Section 2.2 |
| Clinical trial identifier for lactoferrin in male fertility | NCT05171504 | Section 2.1 |
| Field | Value | Source |
|---|---|---|
| Quantitative clinical efficacy data for adult lactoferrin supplementation | null | null |
| Standardized dosage protocols for therapeutic lactoferrin administration | null | null |
| Field | Value | Source |
|---|---|---|
| Molecular weight of lactoferrin | about 80 kDa | 2. Structure and properties of lactoferrin |
| Lactoferrin sequence identity with serum transferrin | 60% | 2. Structure and properties of lactoferrin |
| Lactoferrin iron saturation limit | does not exceed 10% | 2. Structure and properties of lactoferrin |
| Human blood lactoferrin concentration range | 0.02–1.52 μg/ml | 3. Sources of lactoferrin in the organism |
| Human venous plasma lactoferrin concentration | 0.12 μg/ml | 8. Lactoferrin in different species |
| Human colostrum lactoferrin concentration | 3.1–6.7 mg/ml | 8. Lactoferrin in different species |
| Human milk lactoferrin concentration | 1.0–3.2 mg/ml | 8. Lactoferrin in different species |
| Bovine milk lactoferrin concentration range | 1.15 μg/ml to 485.63 μg/ml | 8. Lactoferrin in different species |
| Mare colostrum lactoferrin concentration | 21.7 μg/ml | 8. Lactoferrin in different species |
| Newborn foal serum lactoferrin concentration | 0.249 μg/ml | 8. Lactoferrin in different species |
| Three day old foal serum lactoferrin concentration | 0.445 μg/ml | 8. Lactoferrin in different species |
| Camel milk mean lactoferrin concentration | 0.229 ± 0.135 mg/ml | 8. Lactoferrin in different species |
| Canine milk lactoferrin concentration | 40 μg/ml | 8. Lactoferrin in different species |
| Osteoblast apoptosis reduction by lactoferrin | 50–70% | 7.9. Lactoferrin and bones |
| Lactoferrin concentration for tumor cell cytolysis stimulation | 10 μg/ml | 7.7. Lactoferrin and tumor growth |
| Lactoferrin concentration for tumor cell cytolysis phenotype dependence | 100 μg/ml | 7.7. Lactoferrin and tumor growth |
| Field | Value | Source |
|---|---|---|
| Quantitative data on lactoferrin concentrations in species other than human, bovine, mare, camel, and canine | null | null |
| Standardized reference values for lactoferrin across different age groups and genders | null | null |
| Field | Value | Source |
|---|---|---|
| Lactoferrin concentration in human milk | 2 mg/cm3 | Table 1 |
| Lactoferrin concentration in saliva | 0.01-0.05 mg/cm3 | Table 2 |
| Lactoferrin concentration in tears | 0.01 mg/cm3 | Table 2 |
| Lactoferrin concentration in nasal secretions | 0.01 mg/cm3 | Table 2 |
| Lactoferrin concentration in hepatic bile | 0.01-0.04 mg/cm3 | Table 2 |
| Lactoferrin concentration in pancreatic juices | 0.05-0.10 mg/cm3 | Table 2 |
| Lactoferrin concentration in pseudocyst fluid | 0.5 mg/cm3 | Table 2 |
| Lactoferrin concentration in ascites fluid | 0.5-1.0 mg/cm3 | Table 2 |
| Lactoferrin concentration in seminal fluid | 0.5-1.0 mg/cm3 | Table 2 |
| Lactoferrin concentration in cervical mucus | 0.5-1.0 mg/cm3 | Table 2 |
| Lactoferrin concentration in urine | 0.001 mg/cm3 | Table 2 |
| Zinc concentration in human milk (day 1) | 10 ± 5 µg/g | Section 1.3.1 |
| Zinc concentration in human milk (day 14) | 3.14 ± 1.35 µg/g | Section 1.3.1 |
| Zinc concentration in human milk (10 weeks) | 1.31 ± 0.5 µg/g | Section 1.3.1 |
| Iron concentration in human milk (day 1) | 1.9 ± 5.6 µg/g | Section 1.3.1 |
| Iron concentration in human milk (thereafter) | 0.8 µg/g | Section 1.3.1 |
| Field | Value | Source |
|---|---|---|
| Effect of perchlorate and other anions on Fe2Lf and Cu2Lf | null | null |
| Detailed binding site stoichiometry for manganese and cobalt complexes | null | null |
| Field | Value | Source |
|---|---|---|
| EBAC/HIC processing capacity | 10-20 grams in a single operation | Abstract |
| RCFE processing capacity (small scale) | 1.5g total protein per hour | Abstract |
| FFIEF sub-fractionation capacity | 100mg of immuno-purified rhPC into 50 fractions | Abstract |
| FFIEF pH gradient range | 3-10 using 2% ampholytes | Abstract |
| IgG concentration in pig milk | 1 to 3 mg/ml | Table I, Chapter 1 |
| IgM concentration in pig milk | 3 to 4 mg/ml | Table I, Chapter 1 |
| IgA concentration in pig milk | 3 to 9 mg/ml | Table I, Chapter 1 |
| rhPC anticoagulant activity (EBA-HIC purified) | 71% relative to immuno-purified plasma derived hPC | Table II, Chapter 2 |
| EBAC-SPA IgG purification yield (from IgA/IgM depleted whey) | 92% +/- 9% | Table IIA, Appendix A |
| RCFE rhPC purification yield (anode product) | 95% +/- 8% | Table I, Chapter 4 |
| FFIEF rhPC recovery rate | 90 mass% +/- 6 mass% | Chapter 5, Results |
| Field | Value | Source |
|---|---|---|
| Pathogen clearance validation data | null | null |
| Long-term stability data for purified rhPC | null | null |
| Detailed cost-benefit analysis of large-scale implementation | null | null |
| Field | Value | Source |
|---|---|---|
| Lactoferrin molecular weight | ~80 kDa | Abstract |
| MIC of lactoferricin B for E. coli strains | Table 5.1 | Table 5.1 |
| MBC of lactoferricin B for E. coli strains | Table 5.2 | Table 5.2 |
| Lactoferrin concentrations in human and bovine secretions | Table 1.2 | Table 1.2 |
| Binding parameters of lactoferrin variants to E. coli LPS | Table 1.5 | Table 1.5 |
| Field | Value | Source |
|---|---|---|
| Recombinant protein yield after purification | null | null |
| Solubility data for recombinant lactoferricins after urea removal | null | null |
| Quantitative analysis of membrane blister frequency in resistant E. coli | null | null |
| Field | Value | Source |
|---|---|---|
| Target protein | human lactoferrin | Abstract |
| Host organism for production | A. Oryzae | Abstract |
| Field | Value | Source |
|---|---|---|
| Yield of recombinant human lactoferrin | null | null |
| Purity of recombinant human lactoferrin | null | null |
| Comparison of recombinant protein activity to native protein | null | null |
| Field | Value | Source |
|---|---|---|
| Protein separation method | Ion exchange column chromatography at fixed pH and fixed salt concentration | Abstract |
| Field | Value | Source |
|---|---|---|
| Experimental yield or purity data | null | null |
| Specific pH and salt concentration values | null | null |
| Protein mixture composition | null | null |
| Field | Value | Source |
|---|---|---|
| Process for purifying lactoferrin | Filtration of milk into a retentate fraction (lactoferrin) and a permeate fraction (growth factors and/or RNAses) with prior or concurrent salt treatment | Abstract |
| Field | Value | Source |
|---|---|---|
| Purity percentage of lactoferrin | null | null |
| Yield of lactoferrin recovery | null | null |
| Specific salt concentration used for treatment | null | null |
| Filtration membrane specifications | null | null |